SenzaCell Dendritic-like Myeloid Leukemia Cell Line for GARD Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The use of primary dendritic cells as a test platform is hindered by their multifaceted phenotypes, specialized functions, and scarce distribution, making it difficult to establish accurate and reliable in vitro assays for predicting sensitization, and existing dendritic-like cell lines, such as MUTZ-3, require complex culture protocols.
Innovation Solution
A non-naturally occurring dendritic-like myeloid leukemia cell line, SenzaCell, is developed and compared to MUTZ-3, offering a simpler and more reliable alternative for use in Genomic Allergen Rapid Detection (GARD) assays, with phenotypic, transcriptional, and functional analyses demonstrating shared functionality and quantifiable differences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If primary dendritic cells are used as a test platform, then accurate prediction of sensitization can be achieved, but their multifaceted phenotypes, specialized functions, and scarce distribution make it difficult to establish reliable in vitro assays
Solution Approach 1:
The patent uses dendritic-like cell lines (MUTZ-3 and SenzaCell) as simplified copies of primary dendritic cells. These cell lines replicate the essential immunological functions needed for sensitizer detection while eliminating the complexities associated with primary DCs, including their multifaceted phenotypes and scarcity issues. The cell lines maintain the key transcriptional response patterns to sensitizers without requiring complex isolation and culture procedures.
2Reliability
If MUTZ-3 dendritic-like cell line is used in GARD assays, then sensitization prediction can be performed, but complex culture protocols with feeder cell lines are required
Solution Approach 1:
The patent extracts and eliminates the requirement for feeder cell lines from the MUTZ-3 culture system. The SenzaCell line was specifically developed to function independently without needing IL-3 producing feeder cells, thereby removing a major source of protocol complexity while maintaining the cell line's reliability for GARD assay applications.
Solution Approach 2:
SenzaCell is designed to be self-sufficient in culture, producing its own necessary growth factors and maintaining stable phenotypic characteristics without external support from feeder cells. This self-service capability allows the cells to be cultured using simple, defined media conditions, greatly ease of operation while preserving assay reliability.
3Stability of the object's composition
If dendritic-like cell lines are used instead of primary DCs, then variability and difficulty in obtaining primary DCs are circumvented, but existing lines require complex culture conditions
Solution Approach 1:
SenzaCell creates a stable, simplified copy of the dendritic cell system that captures the essential transcriptional response to sensitizers. The cell line was engineered to maintain stable phenotypic and transcriptional characteristics across passages without requiring complex culture conditions, thereby providing both stability and simplicity simultaneously.
Data Source
AI summary
The present invention provides a non-naturally occurring dendritic-like myeloid leukaemia cell according to ATCC Patent Deposit Designation PTA-123875, and methods and kits utilising such cells.